Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use

被引：1

作者：

Kaplan, David ^{[1
]}

Husni, Elaine ^{[2
]}

Chang, Eunice ^{[3
]}

S. Broder, Michael ^{[3
]}

Paydar, Caleb ^{[3
]}

Bognar, Kata ^{[3
]}

Yan, Jessie ^{[4
]}

Richter, Sven ^{[5
]}

Desai, Pooja ^{[6
]}

Khilfeh, Ibrahim ^{[7
]}

机构：

[1] Adult & Pediat Dermatol, Overland Pk, KS 66211 USA

[2] Cleveland Clin, Dept Rheumat & Immunol Dis, Cleveland, OH 44195 USA

[3] Partnership Hlth Analyt Res LLC, Beverly Hills, CA 90212 USA

[4] Roche, San Francisco, CA 94080 USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Janssen Pharmaceut, Titusville, NJ 08560 USA

[7] Janssen Pharmaceut, Raritan, NJ 08869 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2022年 / 11卷 / 08期

关键词：

administrative claims analysis; biologic initiation; DMARD; oral small molecules; PLAQUE PSORIASIS; ARTHRITIS; EFFICACY; CARE; PREDICTORS; MANAGEMENT; MODERATE; SAFETY; AGE;

D O I：

10.2217/cer-2021-0311

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To compare rates of biologic initiation after commencing treatment with apremilast (APR) versus methotrexate (MTX) in systemic-naive patients with psoriasis (PsO). Methods: This was a retrospective cohort study of systemic-naive patients with PsO who initiated treatment with APR or MTX between 1 January 2015 and 31 March 2018. Outcomes: Adjusted rates of biologic initiation during follow-up were compared by logistic and Cox regressions. Results: APR initiators had 58% lower likelihood of biologic initiation (odds ratio: 0.42; 95% CI: 0.37-0.48; p < 0.001), lower adjusted biologic initiation rate (14.4% [95% CI: 13.2-15.7%] vs 28.6% [95% CI: 26.8-30.5%]), lower risk of biologic initiation (hazard ratio: 0.45; 95% CI: 0.40-0.51; p < 0.001) compared with MTX initiators. Conclusion: Systemic-naive patients with PsO have a lower rate of biologic initiation over 1 year following APR initiation.

引用

页码：575 / 582

页数：8

共 25 条

[1] Agency for Healthcare Research and Quality, 2015, HCUP CHRON COND IND
[2] French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults
Amatore, F.
Villani, A. -P.
Tauber, M.
Viguier, M.
Guillot, B.
Aubin, Francois
Bachelez, Herve
Beneton, Nathalie
Beylot-Barry, Marie
Jullien, Denis
Mahe, Emmanuel
Paul, Carle
Richard, Marie-Aleth
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 464 - 483
[3] Psoriasis Prevalence in Adults in the United States
Armstrong, April W.
Mehta, Manan D.
Schupp, Clayton W.
Gondo, George C.
Bell, Stacie J.
Griffiths, Christopher E. M.
[J]. JAMA DERMATOLOGY, 2021, 157 (08) : 940 - 946
[4] Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis
Armstrong, April W.
Betts, Keith A.
Sundaram, Murali
Thomason, Darren
Signorovitch, James E.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (04) : 740 - 746
[5] Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009
Asgari, Maryam M.
Wu, Jashin J.
Gelfand, Joel M.
Salman, Craig
Curtis, Jeffrey R.
Harrold, Leslie R.
Herrinton, Lisa J.
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (08) : 842 - 849
[6] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
CHARLSON, ME
POMPEI, P
ALES, KL
MACKENZIE, CR
[J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
[7] Pattern and Predictors of the Initiation of Biologic Agents for the Treatment of Rheumatoid Arthritis in the United States: An Analysis Using a Large Observational Data Bank
DeWitt, Esi Morgan
Lin, Li
Glick, Henry A.
Anstrom, Kevin J.
Schulman, Kevin A.
Reed, Shelby D.
[J]. CLINICAL THERAPEUTICS, 2009, 31 (08) : 1871 - 1880
[8] ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES
DEYO, RA
CHERKIN, DC
CIOL, MA
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) : 613 - 619
[9] Feldman SR, 2016, AM HEALTH DRUG BENEF, V9, P504
[10] Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics
Geale, K.
Henriksson, M.
Schmitt-Egenolf, M.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (03) : 579 - 587

← 1 2 3 →